Integrated Molecular, Clinicopathological and Immune Profiling of Non-Small Cell Lung Cancer: The MONREPOS Hellenic Cooperative Oncology Group (HeCOG) Study (HE_2TR/13)
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27198724 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Konstantinos Efthymiadis und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Papageorgiou Hospital, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, 56403 Th…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hellenic Society of Medical Oncology (HeSMO), Hellenic Cooperative Oncology Group.
Abstract (Originalsprache)
Integrated assessment of tumour genomics and immune biomarkers may improve prognostic stratification in non-small cell lung cancer (NSCLC). We examined the distribution and prognostic relevance of somatic pathogenic/likely pathogenic variants (PVs), somatic copy-number alterations (SCNAs), programmed death-ligand 1 (PD-L1) expression and tumour-infiltrating lymphocytes (TILs) in a multicentre cohort. This retrospective, multicentre study included 367 unselected patients with histologically confirmed NSCLC treated at 19 centres in Greece between 2000 and 2020. Targeted next-generation sequencing (NGS) was performed in 267 tumours; PD-L1 tumour proportion score (TPS) and haematoxylin and eosin (H&E)-based TIL density were evaluated in 298 and 352 tumours, respectively. Overall survival (OS) was assessed using Kaplan–Meier and multivariable Cox regression analyses. TP53 (53.6%) and KRAS (16.5%) were the most frequently detected genes with PVs; SCNAs were identified in 22.5% of sequenced tumours and were more frequent in squamous than non-squamous histology. In multivariable analysis (254 complete cases), TIL density ≥10% (hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.52–0.99; p = 0.042) and ≥2 mutated genes (HR 1.44, 95% CI 1.08–1.92; p = 0.014) were independently associated with OS. PIK3CA-containing copy-number gains were significantly enriched in squamous tumours with low TIL density (p = 0.024), while FGFR1-containing copy-number gains showed a similar but non-significant trend (p = 0.088). In the present retrospective study, co-mutation burden and TIL density provided complementary prognostic information beyond clinicopathological variables in NSCLC. The association between selected copy-number gains and an immune-poor squamous phenotype warrants prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Papageorgiou Hospital, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, 56403 Thessaloniki, Greece.
- Medicover Genetics, 2409 Nicosia, Cyprus.
- Department of Pathology, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
- Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, 54124 Thessaloniki, Greece.
- 2nd Department of Pathology, Attikon University Hospital, National and Kapodistrian University of Athens, 12461 Athens, Greece.
- Lung Cancer Oncology Unit, Pulmonary Department, G. Papanikolaou Hospital, Aristotle University of Thessaloniki, 57010 Thessaloniki, Greece.
ORCID-Profile: Chrysa Soteriou, Kyriaki Papadopoulou, Abraham Pouliakis, Mattheos Bobos, Konstantinos Kyritsis, Paris A Kosmidis, Flora Zagouri, Eleni Timotheadou, Prodromos Hytiroglou, Alexia Eliades, George Fountzilas
Förderung
- Hellenic Society of Medical Oncology (HeSMO)
- Hellenic Cooperative Oncology Group
Zitieren
APA
Efthymiadis, K., Soteriou, C., Kotoula, V., Papadopoulou, K., Pouliakis, A., Lampaki, S., Goussia, A., Fountzilas, E., Meditskou, S., Bobos, M., Kyritsis, K., Lemesios, C., Samantas, E., Sarris, E., Pentheroudakis, G., Bafaloukos, D., Pectasides, D., Kosmidis, P. A., Zagouri, F., …, & Linardou, H. (2026). Integrated Molecular, Clinicopathological and Immune Profiling of Non-Small Cell Lung Cancer: The MONREPOS Hellenic Cooperative Oncology Group (HeCOG) Study (HE_2TR/13). International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27198724
Vancouver
Efthymiadis K, Soteriou C, Kotoula V, Papadopoulou K, Pouliakis A, Lampaki S, et al. Integrated Molecular, Clinicopathological and Immune Profiling of Non-Small Cell Lung Cancer: The MONREPOS Hellenic Cooperative Oncology Group (HeCOG) Study (HE_2TR/13). International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27198724
BibTeX
@article{Efthymiadis2026,
author = {Efthymiadis, Konstantinos and Soteriou, Chrysa and Kotoula, Vassiliki and Papadopoulou, Kyriaki and Pouliakis, Abraham and Lampaki, Sofia and Goussia, Anna and Fountzilas, Elena and Meditskou, Soultana and Bobos, Mattheos and Kyritsis, Konstantinos and Lemesios, Christos and Samantas, Epaminontas and Sarris, Evangelos and Pentheroudakis, George and Bafaloukos, Dimitrios and Pectasides, Dimitrios and Kosmidis, Paris A and Zagouri, Flora and Spyratos, Dionysis and Timotheadou, Eleni and Hytiroglou, Prodromos and Eliades, Alexia and Koumbaris, George and Fountzilas, George and Linardou, Helena},
title = {Integrated Molecular, Clinicopathological and Immune Profiling of Non-Small Cell Lung Cancer: The MONREPOS Hellenic Cooperative Oncology Group (HeCOG) Study (HE_2TR/13)},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27198724}
}
EUVIMED